1. Generics Bulletin
  2. >>Leadership

Who’s Hired? Lupin Appoints CEO To New API CDMO Subsidiary

ChemWerth’s CEO And President Passes On Reins To His Son

 
• By Urtė Fultinavičiūtė

Lupin has selected a CEO to lead its fresh API CDMO business venture, while the UK’s off-patent group BGMA has appointed a new vice-chair. Meanwhile, ChemWerth has welcomed a familiar face as its new president and Coherus has elected a new board member with a focus on immuno-oncology.

Concept of hiring people
• Source: Shutterstock

Indian generics firm Lupin has accomplished two things at once – announced a freshly formed subsidiary Lupin Manufacturing Solutions and appointed a CEO to lead the new business venture.

Abdelaziz Toumi brings over two decades of experience in the biotech, pharma, and contract development and manufacturing operations sectors, spanning...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Medicines UK’s Samuels: Off-Patent Drugs Are Finally Gov’s Priority But The Picture Still ‘Nuanced’

 
• By Urtė Fultinavičiūtė

The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. But, as Medicines UK’s CEO Mark Samuels tells Generics Bulletin, companies are still facing multiple hurdles in the market.

‘By Most Measures A Failure’: Ten Years On From Teva-Actavis

 
• By Dean Rudge

A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis.

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

 
• By Dave Wallace

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By Dave Wallace

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.

More from Generics Bulletin

Sandoz Rushes To Fill Gap After German Court Revokes Xarelto Patent

 
• By Dean Rudge

Germany’s Federal Patent Court has invalidated Bayer’s key patent covering once-daily use of Xarelto (rivaroxaban), paving the way for Sandoz to launch a generic version. Bayer is considering an appeal.

Samsung Bioepis’ Second Quarter Comes Down From Milestone-Boosted Q2 2024

 
• By Urtė Fultinavičiūtė

With the looming spin-off on the horizon, Samsung Bioepis looks at planned product launches and geographic expansion to maintain its annual revenue growth.

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.